These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1904652)

  • 1. Adverse effects of treatment with porcine factor VIII.
    Gringeri A; Santagostino E; Tradati F; Giangrande PL; Mannucci PM
    Thromb Haemost; 1991 Mar; 65(3):245-7. PubMed ID: 1904652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of porcine factor VIII in the management of seventeen patients with factor VIII antibodies.
    Gatti L; Mannucci PM
    Thromb Haemost; 1984 Jul; 51(3):379-84. PubMed ID: 6437005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors.
    Lozier JN; Santagostino E; Kasper CK; Teitel JM; Hay CR
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):10-21. PubMed ID: 8480192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile of porcine factor VIII and its use as hospital and home-therapy for patients with haemophilia-A and inhibitors: the results of an international survey.
    Hay CR; Lozier JN; Lee CA; Laffan M; Tradati F; Santagostino E; Ciavarella N; Schiavoni M; Fukui H; Yoshioka A; Teitel J; Mannucci PM; Kasper CK
    Thromb Haemost; 1996 Jan; 75(1):25-9. PubMed ID: 8713775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience.
    Brettler DB; Forsberg AD; Levine PH; Aledort LM; Hilgartner MW; Kasper CK; Lusher JM; McMillan C; Roberts H
    Arch Intern Med; 1989 Jun; 149(6):1381-5. PubMed ID: 2499293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
    Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
    Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of JM9 in advanced ovarian cancer: a phase I-II trial.
    Bramwell VH; Crowther D; O'Malley S; Swindell R; Johnson R; Cooper EH; Thatcher N; Howell A
    Cancer Treat Rep; 1985 Apr; 69(4):409-16. PubMed ID: 3995511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections.
    Bidlingmaier C; Deml MM; Kurnik K
    Haemophilia; 2006 May; 12(3):212-7. PubMed ID: 16643203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
    Mariani G; Kroner B;
    Haematologica; 2001 Nov; 86(11):1186-93. PubMed ID: 11694405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of porcine factor VIII in France.
    Negrier C
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):29-32. PubMed ID: 7939770
    [No Abstract]   [Full Text] [Related]  

  • 13. Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: efficacy, patient selection, and side effects.
    Hay CR; Lozier JN; Lee CA; Lafan M; Tradati H; Santagostino E; Ciavarella N; Schiavoni M; Fukui H; Yoshioka A
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):20-5. PubMed ID: 7939768
    [No Abstract]   [Full Text] [Related]  

  • 14. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of anti-human and anti-porcine factor VIII antibody titers in patients with hemophilia].
    Windyga J; Rzymkiewicz L; Lopaciuk S
    Acta Haematol Pol; 1996; 27(1):27-31. PubMed ID: 8629440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
    Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG
    Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological markers of autoimmunity in patients with hemophilia A: the role of hepatitis C virus infection, alpha-interferon and factor VIII treatment in skewing the immune system toward autoreactivity.
    Vianello F; Tison T; Tagariello G; Zerbinati P; Zanon E; Scarano L; Girolami A
    Blood Coagul Fibrinolysis; 1999 Sep; 10(6):393-7. PubMed ID: 10493222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of porcine factor VIII in Japan.
    Yoshioka A; Shima M; Morichika S; Terada S; Fukui H
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):26-8. PubMed ID: 7939769
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates.
    von Auer Ch; Oldenburg J; von Depka M; Escuriola-Ettinghausen C; Kurnik K; Lenk H; Scharrer I
    Ann N Y Acad Sci; 2005 Jun; 1051():498-505. PubMed ID: 16126990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.